M-Ras distinct activation scenarios: A mechanistic outlook and targeting

Area of Science:

• Molecular biology
• Biochemistry
• Pharmacology

Background:

• Canonical Ras GTPases (H-, K-, N-Ras) have defined nucleotide-exchange and effector binding capabilities based on conformational states.
• M-Ras, a Ras GTPase, exhibits distinct behavior, with its GTP-bound form predominantly in an inactive state, unlike canonical Ras.
• M-Ras's active state is stabilized within a ternary complex involving SHOC2 scaffolding protein and protein phosphatase-1 (PP1), which influences MAPK signaling and contributes to Noonan syndrome.

Purpose of the Study:

• To investigate the distinct conformational dynamics of M-Ras and its activating variant M-Ras^Q71R in both GTP- and GDP-bound states.
• To elucidate the allosteric mechanisms differentiating M-Ras from canonical Ras GTPases.
• To identify potential therapeutic strategies for targeting M-Ras and its variants in diseases like cancer.

Main Methods:

• All-atom molecular dynamics simulations were employed to analyze the conformational dynamics of M-Ras and M-Ras^Q71R.
• Simulations were conducted for both GTP- and GDP-bound states to capture nucleotide-dependent conformational changes.
• Analysis focused on switch regions and nucleotide-binding coordination to understand functional differences.

Main Results:

• M-Ras and M-Ras^Q71R exhibit differential GTP/GDP loading and distinct conformational dynamics in their switch regions, though both favor inactive conformations.
• The conserved asparagine residue in the M-Ras G4-loop was identified as the weakest point in nucleotide-binding coordination, providing insight into GDP release.
• The Switch II pocket is occluded by a mobile Switch II region, suggesting it may be an unfavorable target for drug development.

Conclusions:

• M-Ras and canonical Ras GTPases possess distinct allosteric mechanisms that shape their function and influence drug discovery approaches.
• Targeting the M-Ras^Q71R binding interface with specific inhibitors, such as optimized K-Ras inhibitors or cyclophilin A, presents a viable alternative therapeutic strategy.
• Understanding the unique conformational dynamics of M-Ras is crucial for developing effective treatments for M-Ras-associated cancers and other conditions.